Helsinn sets up a bou­tique in­vest­ment fund with a rov­ing eye for on­col­o­gy up­starts

If you’re start­ing up an ear­ly-stage biotech fo­cused on can­cer R&D, Helsinn has set up a bou­tique ven­ture arm that just might be in­ter­est­ed in step­ping in at the ground floor.

Un­til now, the Swiss com­pa­ny has been fo­cus­ing its at­ten­tion on can­cer sup­port­ive care, pri­mar­i­ly back­ing late-stage work. But the new Helsinn In­vest­ment Fund is de­signed to join syn­di­cates with an eye for ear­ly stage plays.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.